Cantor Fitzgerald Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS)

Research analysts at Cantor Fitzgerald began coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a research report issued on Tuesday, MarketBeat reports. The firm set an “overweight” rating on the biotechnology company’s stock.

Other equities research analysts also recently issued research reports about the stock. Leerink Partners raised shares of Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $2.00 to $7.00 in a research report on Tuesday, November 19th. Jefferies Financial Group raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and boosted their price objective for the company from $2.00 to $7.00 in a research report on Tuesday, November 19th. Piper Sandler raised shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $3.00 to $13.00 in a research report on Monday, November 18th. Leerink Partnrs raised shares of Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 19th. Finally, StockNews.com downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 8th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $11.67.

Aclaris Therapeutics Stock Down 1.9 %

Shares of NASDAQ ACRS opened at $1.55 on Tuesday. Aclaris Therapeutics has a twelve month low of $0.95 and a twelve month high of $5.17. The firm has a market cap of $167.27 million, a P/E ratio of -2.98 and a beta of 0.48. The company has a 50 day moving average of $2.20 and a 200 day moving average of $2.21.

Institutional Trading of Aclaris Therapeutics

Hedge funds have recently bought and sold shares of the stock. ExodusPoint Capital Management LP purchased a new stake in Aclaris Therapeutics in the 4th quarter worth $26,000. Invesco Ltd. purchased a new stake in shares of Aclaris Therapeutics during the 4th quarter valued at about $28,000. Graham Capital Management L.P. purchased a new stake in shares of Aclaris Therapeutics during the 4th quarter valued at about $35,000. Commonwealth Equity Services LLC purchased a new stake in shares of Aclaris Therapeutics during the 4th quarter valued at about $36,000. Finally, Alpine Global Management LLC purchased a new stake in shares of Aclaris Therapeutics during the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.